Low tissue levels of miR-125b predict malignancy in solitary fibrous tumors of the pleura by Brock, Matthias et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
Low tissue levels of miR-125b predict malignancy in solitary fibrous tumors
of the pleura
Brock, Matthias; Hottinger, Selma; Diebold, Matthias; Soltermann, Alex; Jochum, Wolfram; Kohler,
Malcolm; Huber, Lars C; Franzen, Daniel P
DOI: https://doi.org/10.1186/s12931-017-0528-7
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-137734
Published Version
 
 
Originally published at:
Brock, Matthias; Hottinger, Selma; Diebold, Matthias; Soltermann, Alex; Jochum, Wolfram; Kohler,
Malcolm; Huber, Lars C; Franzen, Daniel P (2017). Low tissue levels of miR-125b predict malignancy in
solitary fibrous tumors of the pleura. Respiratory Research, 18(1):1-8.
DOI: https://doi.org/10.1186/s12931-017-0528-7
RESEARCH Open Access
Low tissue levels of miR-125b predict
malignancy in solitary fibrous tumors of the
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Abstract
Background: Solitary fibrous tumors of the pleura (SFTP) are rare neoplasia of the chest. A subset of SFTP follows a
malignant course, sometimes several years after complete resection. Traditional scoring systems based on clinical and
histological features are poor predictors of biological behavior. This study aimed to investigate tumor-associated miRNAs
expression as novel biomarkers to predict the clinical behavior of SFTP.
Methods: Formalin-fixed and paraffin-embedded SFTP tissues blocks from patients surgically resected between 1992
and 2013 at two tertiary care teaching hospitals were included. SFTP tumors were categorized as either malignant or
benign variants according to the WHO classification. Following miRNAs levels were measured: let-7a, miR-16b, miR-17,
miR-21, miR-31, miR-34a, miR-92a, miR-125a, miR-125b, miR-195-5b, miR-203a, and miR-223. Differential gene expressions
which were calculated with the threshold cycle (Ct) method were compared among the two variants.
Results: Thirty-eight patients (40% male, mean age 62.2 (±10.9) years) were included. Expression levels of miR-
125b showed a significant difference between benign compared to malignant variants (−3.08 ± 0.93 vs. -2.22
± 1.36, p = 0.0068). Furthermore, lower levels of miR-125b were found to be associated with increased tumor
size (p = 0.0414). Thus, downregulation of miR-125b indicates malignant transformation. All other investigated
miRNAs were not associated with grading of SFTP.
Conclusions: Our data suggest a potential role of miR-125b in the pathogenesis of tumor growth and malignant
transformation of SFTP, respectively. Further studies have to address the potential use of miRNA-125b as a biomarker or
therapeutic target in SFTP.
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Background
Solitary fibrous tumors of the pleura (SFTP) are rare neo-
plasia within the chest cavity with an estimated incidence
of approximately 0.2/100’000 persons per year [1], and ac-
count for 5% of all pleural tumors [2]. Beside the preferred
occurrence in the pleura diverse anatomical locations of
solitary fibrous tumors have been reported [3, 4]. Historic-
ally, SFTP were denominated as “localized mesothelioma”
reflecting the lack of consensus with respect to
pathogenesis and biological behavior of these tumors [5].
Nowadays, SFTP have been shown to arise from mesen-
chymal cells and, as such, express immuno-histochemical
markers including vimentin and CD34 [6, 7]. The majority
of SFTP follow a benign course with a high cure rate after
complete surgical resection [8, 9]. However, malignant
variants with a high risk of local recurrence, metastases,
and increased mortality are found in 7–60% [9–11]. In
addition, some SFTP which were initially assessed to fol-
low a benign course may transform into malignant vari-
ants, sometimes several years after R0-resection [12, 13].
Therefore, characteristics that distinguish benign from
malignant variants are crucial for estimating the risk of an
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adverse outcome, and planning adjuvant therapies and ad-
equate follow-up examinations [5].
England et al. were the first to describe six clinico-
pathologic features predicting a malignant behavior.
These risk factors included tumor size, localization, ses-
sile tumor, existence of necrosis or hemorrhage, high mi-
toses count, and evidence of nuclear pleomorphism [9].
More recently, a staging system based on tumor seating
and on the above mentioned features have been pro-
posed in order to improve identification of malignant
variants [14]. However, several multivariable models
identified these characteristics which are based exclu-
sively on clinico-pathologic features as poor predictors
for the biological behavior of SFTP [15–17]. Yet, there is
insufficient data on immune-histochemical and molecu-
lar markers predicting the outcome of SFTP.
MiRNAs are small non-coding RNA fragments of 20–22
nucleotides in length that are commonly associated with
gene silencing. Since there is growing evidence that miR-
NAs might be of major interest in the diagnosis and
prognosis of different diseases including lung cancer
[18] and mesothelioma [19], this study aimed to in-
vestigate the role of miRNAs as biomarkers to predict
the clinical behavior of SFTP.
Methods
Patients and sample collection
Consecutive patients undergoing surgical resection of SFTP
between 1992 and 2013 at two tertiary care teaching hospi-
tals and with a follow up of at least one month were eligible
for the study. The diagnosis of SFTP was made by the De-
partments of Pathology of either of these institutions, based
on the typical morphologic and immuno-histochemical fea-
tures [9]. Patient data on demographics, clinical presenta-
tion, radiologic features and surgical treatment as well as
follow-up data were extracted from medical records and, if
required, obtained from the patients’ general practitioners.
Formalin-fixed and paraffin-embedded (FFPE) tissue blocks
of all tumors were collected, and a representative slide was
cut and reviewed by a dedicated pulmonary pathologist
(A.S.). Patients with wrong diagnosis of SFTP or missing
FFPE tissue block were excluded from the study. According
to the WHO classification [20], the tumor samples were al-
located to either malignant or benign variants. Thus, the
presence of more than one feature of the traditional classi-
fication system proposed by England et al. [9], including
tumor size greater 10 cm, atypical localization, sessile
morphology, existence of necrosis or hemorrhage, more
than four mitoses per 10 HPF and nuclear polymorphism
were used to define malignant SFTP.
MiRNA Isolation
Total RNA including miRNAs was purified from FFPE
lung tissue slides using the miRCURY RNA Isolation Kit
(Exiqon, Vedbaek, Denmark) as recommended by the
manufacturer. Briefly, human lung tissue was scraped off
from FFPE tissue slides (four slides of 10 μm from each
patient) with a scalpel and placed in Eppendorf tubes.
To remove paraffin from the sections, paraffin dissolver
was added. Next, samples were centrifuged and the
supernatant was removed without disturbing the pellet.
Then Proteinase K was added followed by an incubation
step for 30 min at 56 °C. After addition of precipitation
buffer, the samples were incubated for five minutes on
ice. Next, samples were centrifuged before the super-
natant was transferred to a new tube and incubated for
another 15 min at 80 °C. To adjust binding conditions,
binding buffer was added and incubated for 1 min. Each
sample was loaded on a column to bind the RNA to the
column. The samples were passed through a filter cart-
ridge, centrifuged and the flow through was discarded.
After addition of wash buffer to each column, the
Table 1 Protein targets and corresponding miRNAs
Target miRNA Verification by qPCR Reference
MIB-1
(Ki-67)
miR-21 yes Rask et al. [36]
miR-519d yes Hou et al. [37]
p16 or p53 hsa-miR-31 yes Robinson et al.[38, 39]
let-7a no Akaike et al. [40]
hsa-miR-125b yes Liu et al. [41]
hsa-miR-16 yes Feng et al. [42]
hsa-miR-17 n/a Toledo et. [43]
hsa-miR-195 yes Flavin et al. [44]
hsa-miR-203 n/a Guled et al. [45]
hsa-miR-92a yes Dews et al. [46]
hsa-miR-34a yes Ji et al. [47]
STAT6 hsa-miR-361-5p yes Chung et al. [48]
qPCR quantitative real-time polymerase chain reaction, n/a not available
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samples were again centrifuged. As a following step,
DNA was digested by the addition of DNase I mix to the
center of each filter and incubated for 15 min before
washed twice. This step was necessary to remove DNA
that would otherwise interfere with miRNA quantifica-
tion. Next, RNase-free water was applied to the center of
each filter and the RNA containing samples were centri-
fuged to pass the mixture through the filter. The eluted
RNA was then analyzed for miRNA expression or stored
at −80 °C.
Selection and quantification of mature miRNAs
The first step of this study was focused on the identifica-
tion of dysregulated genes in SFTP. MiRNAs that poten-
tially interact with these genes were retrieved using
PubMed search (Table 1). As such, the levels of the follow-
ing miRNAs were measured: let-7a, miR-16b, miR-17,
miR-21, miR-31, miR-34a, miR-92a, miR-125a, miR-125b,
miR-195-5b, miR-203a, and miR-223. Mature miRNAs
were detected by specific stem-loop primers and reverse
transcribed using GoScript reverse transcriptase (Promega,
Dübendorf, Switzerland). Quantification of complementary
DNA (cDNA) was performed using SYBR Green quantita-
tive PCR (qPCR, Applied Biosystem, StepOnePlus system,
Life Technologies, Zug, Switzerland). Sequences of primers
used in this study for reverse transcription and amplifi-
cation of miRNAs are shown in Table 2. Specific ampli-
fication of the miRNA of interest was confirmed by
melt curve analysis. Differential gene expression was
calculated with the threshold cycle (Ct) method [21].
MiRNA expression levels are shown in Δct values nor-
malized to the levels of RNU48 and RNU49. Higher Δct
values indicate lower abundance of the miRNA of inter-
est and vice versa.
Table 2 Primer sequences
Primer miRNA Sequence
Reverse Universal rev 5’ - GAG GTA TTC GCA CTG GAT AC - 3’
RT RNU-48 5’ - GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACG GTC AG - 3’
Forward RNU-48 5’ - CCA TGA GTG TGT CGC TGA TG - 3’
RT RNU-49 5’ - GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACA ATC AG - 3’
Forward RNU-49 5’ - AAG CGA TAA CTG ACG AAG ACT AC - 3’
RT let-7a 5’ - GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACA ACT AT - 3’
Forward let-7a 5’- CGG TGA GGT AGT AGG TTG TAT - 3’
RT miR-16b 5’ - GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACC GCC AA - 3’
Forward miR-16b 5’- CCT AGC AGC ACG TAA ATA TTG G - 3’
RT miR-17 5’ - GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACC TAC CT - 3’
Forward miR-17 5’ - GCG GCA AAG TGC TTA CAG TG - 3’
RT miR-21 5’ - GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACT CAA CA - 3’
Forward miR-21 5’ - GCC CGC TAG CTT ATC AGA CTG ATG - 3’
RT miR-31 5’ - GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACA GCT AT - 3’
Forward miR-31 5’- CAG GCA AGA TGC TGG CAT AG - 3’
RT miR-34a 5’ - GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACA CAA CC - 3’
Forward miR-34a 5’ - TGG CAG TGT CTT AGC TGG TTG – 3’
RT miR-92a 5’ - GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACA CAG GC - 3’
Forward miR-92a 5’ - CCC TAT TGC ACT TGT CCC G - 3’
RT miR-125a 5’ - GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACT CAC AG - 3’
Forward miR-125a 5’ - TCC CTG AGA CCC TTT AAC C - 3’
RT miR-125b 5’ - GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACT CAC AA - 3’
Forward miR-125b 5’- CTC CCT GAG ACC CTA ACT TG - 3’
RT miR-195-5b 5’ - GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACG CCA AT - 3’
Forward miR-195-5b 5’- GGT AGC AGC ACA GAA ATA TTG G - 3’
RT miR-203a 5’ - GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACC TAG TG - 3’
Forward miR-203a 5’- CCG TGA AAT GTT TAG GAC CAC - 3’
RT miR-223 5’ - GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACT GGG GT - 3’
Forward miR-223 5’- CCC TGT CAG TTT GTC AAA TAC C- 3’
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Statistics
All data are presented as mean ± standard deviation
(SD). Parametric or non-parametric distribution of data
was determined using the Kolmogorov-Smirnov test.
Data comparison between malignant and benign SFTP
variants were performed using independent, two-tailed
Student’s t-test for parametric distribution as well as
Mann–Whitney U test for nonparametric distribution.
Nominal data were compared using the Fisher’s exact
test. Correlation analysis was carried out with Pearson’s
calculations. Values with a p < 0.05 were considered to
be statistically significant (*p < 0.05, **p < 0.01, ***p <
0.001). All statistical calculations were performed using
the software package GraphPad Prism Version 5.0
(GraphPad Software, San Diego, CA, USA).
Results
In total, 38 patients (40% male, mean age 62.2 (±10.9)
years) were included (Fig. 1). Baseline characteristics as
well as the traditional pathological features of SFTP
published by England et al. [9] are summarized in
Table 3. Sixteen patients were found to have malignant
variants according to completion of two, three, or four
to five of these features in seven, four and five patients,
respectively.
Detection and quantification of miRNAs in SFTP
The mean expression levels of all measured miRNAs are
presented in Table 4 and Fig. 2, separated in benign and
malignant SFTP variants according to England et al. [9].
Calculation of fold change difference and statistical ana-
lysis is provided in Table 4. When assessing the expres-
sion levels in benign and malignant variants, substantial
changes were found for different miRNAs. However, due
to high variability between the samples, only alterations
in the expression levels of miR-125b reached statistical
significance (miR-125b in benign SFTP: −3.08 ± 0.93,
miR-125b in malignant SFTP −2.22 ± 1.36, p = 0.0068,
Fig. 2). Thus, all further experiments were performed on
miR-125b.
Levels of miR-125b
As shown in Fig. 3, the expression of miR-125b was
found to be significantly decreased in malignant SFTP
variants (reduction to 69). Next, we analyzed the expres-
sion data of miR-125b in the context of the tumor size.
In malignant SFTP tumor size was significantly in-
creased when compared to benign samples (diameter of
tumors in mm: benign SFTP 79.32 ± 54.32 vs. malignant
SFTP 136.3 ± 73.06, p = 0.0125 Fig. 4a). When tumor size
was compared to miR-125b levels, we found that expres-
sion levels of miR-125b inversely correlated with tumor
size (Fig. 4b), indicating that lower levels are associated
with an increase in tumor size (p = 0.0414). These data
suggest a potential role of miR-125b in the pathogenesis
of tumor growth and malignant transformation of SFTP.
Discussion
In this translational study, we addressed the pattern and
expression levels of miRNAs in SFTP and found that i)
reduced levels of miR-125b are indicative of malignant
Fig. 1 Study flowchart. FFPE, formalin-fixed and paraffin-embedded; SFT,
solitary fibrous tumor
Table 3 Patient characteristics and features of solitary fibrous
tumors of the pleura, n = 38
Characteristics All,
n = 38
Malignant,
n = 16
Benign,
n = 22
p-value*
Male sex 15 (40) 9 (56) 6 (27) 0.09
Age, years 62.2 (10.9) 64.7 (9.2) 60.3 (11.8) 0.24
Sessile morphology 15 (42) 11 (69) 4 (20) 0.006
Nuclear pleomorphism 6 (16) 4 (25) 2 (9) 0.22
Necrosis or hemorrhage 11 (29) 8 (50) 3 (14) 0.028
Tumor size, cm 10.6 (6.7) 13.6 (7.3) 8.3 (5.3) 0.014
Mitoses, n per HPF 4.1 (5.4) 45 (37) 1 (1) <0.0001
>4 mitoses per HPF 11 (28.9) 11 (68.8) 0 (0) <0.0001
Data presented as mean (± SD) or n (%) as appropriate
HPF high-power field
*Statistical analysis by unpaired student’s t-test or Fisher’s exact test as appropriate
Table 4 Expression levels of miRNAs in SFTP
miRNA Ct values in
benign SFTP
Ct values in
malignant SFTP
P values Fold
change
let-7a −1.24 ± 0.79 −1.42 ± 1.33 0.61 1.13
miR-16-5p −4.62 ± 0.67 −4.43 ± 1.14 0.51 0.87
miR-17 0.7 ± 0.78 0.77 ± 1.16 0.67 0.95
miR-21 −0.93 ± 0.97 −1.61 ± 1.75 0.47 1.6
miR-31 8.61 ± 0.91 7.89 ± 2.37 0.2 1.65
miR-34a 1.05 ± 0.83 1.1 ± 1.32 0.69 0.96
miR-92a 1.06 ± 0.53 1.16 ± 0.86 0.65 0.93
miR-125a 1.18 ± 0.56 0.99 ± 0.78 0.38 1.14
miR-125b −3.08 ± 0.93 −2.22 ± 1.36 0.007 0.69
miR-195-5p −1.9 ± 0.66 −1.66 ± 1.08 0.39 0.84
miR-203a 8.45 ± 1.94 8.91 ± 2.62 0.54 0.73
miR-223 0.99 ± 1.21 0.63 ± 1.57 0.93 1.29
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transformation of SFTP and, ii), lower expression of
miR-125b was inversely correlated with tumor size.
The challenge of diagnosis and staging of SFTP is the
prediction of biological behavior. The majority of SFTP fol-
low a benign course, but a considerable high proportion of
these tumors may present with an aggressive behavior in-
cluding distant metastases or recurrence, sometimes sev-
eral years after complete resection [9–13, 22, 23]. For this
reason, several scoring systems have been introduced
which are originally based on six pathological features pro-
posed by England et al. [9, 14]. However, multivariable
models identified these features as poor predictors for the
biological behavior of SFTP [15–17]. And, clinical parame-
ters do not seem to have sufficient discriminative power to
predict the outcome of SFTP [17]. Thus, investigation on
immuno-histochemical and molecular markers is needed
to characterize SFTP and their outcome more accurately.
For example, high p53 expression has been shown to be as-
sociated with adverse outcome of SFTP [15, 24]. Recently,
we found that Ki-67 labeling index (MIB-1), an immuno-
histochemical marker of proliferation, is a promising pre-
dictor for an adverse outcome in SFTP [17]. Due to its role
in ribosomal RNA transcription [25], the Ki-67 antigen is
of special interest in the context of non-coding RNAs pro-
filing. These small RNA fragments have emerged as im-
portant gene regulators and it is estimated that more than
50% of the human genome are controlled by non-coding
RNAs [26]. Within the group of non-coding RNAs, miR-
NAs are the best-characterized to date [27]. As such, miR-
NAs have been implicated in the pathogenesis of disease
and as biomarkers for diagnosis and prognosis. Of interest,
miRNAs have distinct properties that make them interest-
ing biomarker candidates including stability and standard-
ized quantification within tissues and biofluids [28].
Fig. 2 The expression profile of selected miRNAs in FFPE lung tissue slides from SFTP samples. The relative expression levels of selected miRNAs
(let-7a, miR-16b, miR-17, miR-21, miR-31, miR-34a, miR-92a, miR-125a, miR-125b, miR-195-5b, miR-203a, and miR-223) from lung tissue slides of benign
(n = 22) and malignant (n = 16) SFTP samples is shown. The obtained Ct values of miRNAs were normalized to the expression levels of the mean of the
endogenous controls RNU48 and RNU49. Statistical analysis by unpaired student’s t-test or Mann–Whitney U test. **p < 0.001
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Here we employed a screening approach and assessed
the expression levels of selected miRNAs in clinically
well-characterized samples of SFTP. Isolation and quan-
tification of miRNAs was performed in formalin-fixed
and paraffin-embedded (FFPE) tissue blocks. This
method has been described before [29, 30] and was re-
cently confirmed as a feasible technology by our own
work using lung tissue slides [31]. These data, together
with the results provided here, highlight both the reli-
ability and the reproducibility by which miRNAs are iso-
lated and quantified from FFPE.
Of interest, out of a panel of selected miRNAs that have
previously been associated with lung cancer [18], only the
expression of miR-125b was found to be significantly al-
tered when benign and malignant variants of SFTP were
compared. miR-125b has been identified as an important
oncomir [32] that is dysregulated in many different types
of cancers including breast cancer [33], hepatocellular and
cologastric carcinoma [34] and thyroid neoplasias [35].
Since both up and down regulation of miR-125b have
been described in cancer, it was suggested that miR-125b
has tissue or cell-type specific effects [32]. In this context,
miR-125b was linked to aberrant regulation of several tar-
get genes involved in the control of differentiation, prolif-
eration and apoptosis [32]. Whether and which of these
mechanisms apply to SFTP is beyond the scope of this de-
scriptive analysis and remains unclear to date. However,
since tumor size was significantly correlated with expres-
sion levels of miR-125b, our results here provide evidence
that, in addition to mediating malignant transformation of
SFTP, miR-125b might have pro-proliferative and anti-
apoptotic effects on pleural cells.
Our study is mainly limited by its descriptive design
and by a relatively low patient number. However, by ana-
lyzing a substantial number of samples obtained from
two different tertiary care centers, this is the first report
on a pathogenetic role of miRNAs in SFTP. Further-
more, since there are concerns regarding the accuracy of
the traditional grading systems of SFTP [15–17], miR-
125b should be prospectively investigated in a future
study with higher sample size. Moreover, the discrimina-
tive power of miR-125b should be confirmed with out-
come data and other immunohistochemical parameters
(e.g. p53 expression or MIB-1 rather than traditional
grading systems. However, due to the low sample size
we were not able to overcome this limitation.
Fig. 3 The expression of miR-125b is significantly reduced in malignant
SFTP samples. The expression of miR-125b in benign (n = 22) and
malignant SFTP samples (n = 16) was measured by qPCR analysis.
Statistical analysis by unpaired student’s t-test. ** p < 0.001
Fig. 4 Significant inverse correlation between miR-125b levels and tumor size in SFTP. a The size of tumors in benign (n = 22) and malign SFTP (n = 16)
presented as diameter in mm is shown. b Correlation analysis of miR-125b levels with the size of tumors in SFTP. Statistical analysis by Mann–Whitney U
test (a). Correlation analysis was carried out with Pearson’s calculations (b). *p < 0.05
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Conclusions
Our data show that lower miR-125b expression levels
are associated with an increase in tumor size and that
downregulation of miR-125b indicates malignant trans-
formation. These data emphasize a role of miR-125b in
the clinical course of SFTP. Further studies have to ad-
dress the potential use of miR-125b as a biomarker or
therapeutic agent in SFTP.
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